Clinical commentary on ‘Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis’

Abstract

Keywords

Alemtuzumab infection safety immunosuppression risk management

Get full access to this article

View all access options for this article.

References

Russo

Saccà

Paternoster

, et al. Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. Mult Scler 2020; 26: 123–126.

Buonomo

Zappulo

Viceconte

, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018; 17(7): 709–717.

Coles

Robertson

Al-Araji

, et al. Guidance on the prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis, 2018, https://www.theabn.org/media/Guidance%20on%20the%20prevention%20of%20Listeria%20infection%20after%20alemtuzumab%20treatment%20of%20multiple%20sclerosis.pdf

Grulich

vanLeeuwen

Falster

, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370(9581): 59–67.